Evidence map›Paper›PMID 28288036›Full record

ArticleThe American journal of surgical pathology2017

GIST Manifesting as a Retroperitoneal Tumor: Clinicopathologic Immunohistochemical, and Molecular Genetic Study of 112 Cases.

Markku Miettinen, Anna Felisiak-Golabek, Zengfeng Wang, Shingo Inaguma, Jerzy Lasota

Abstract read
In one paragraph

Article in The American journal of surgical pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Domestic research on extra-gastrointestinal stromal tumors: A ten-year review.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Molecular Profiling ofCancers · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Retroperitoneal extra gastrointestinal stromal tumor: A case report.International journal of surgery case reports · 2023
    Article
  11. Article
  12. Article
  13. Current surgical management of duodenal gastrointestinal stromal tumors.World journal of gastrointestinal surgery · 2021
    Review
  14. A multidisciplinary approach in the diagnostic challenge of GIST.Experimental and therapeutic medicine · 2021
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Markku Miettinen*Laboratory of Pathology, National Cancer Institute, Bethesda, MD †Aichi Medical University School of Medicine, Nagakute, Japan.
Anna Felisiak-Golabek
Zengfeng Wang
Shingo Inaguma
Jerzy Lasota
National Cancer Institute · US

Funding

Genreal Surgical PathologyZIDBC011291 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2010 to 2025
$30.3M
Immunohistochemical and genomic analysis of tumorsZIABC011427 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MIETTINEN, MARKKU · 2012 to 2025
$24.0M
Intramural NIH HHS Z99 CA999999
6 · The paper itself

Abstract

Most gastrointestinal stromal tumors (GISTs) occur in the tubular gastrointestinal (GI) tract, but some present apparently outside the GI tract. In this study, we analyzed 112 GISTs located in the retroperitoneum. These tumors occurred in 55 women and 57 men with a median age of 65 years (range: 21 to 89 y). On the basis of clinically or histologically detected connections to GI tract, 15 tumors were considered likely of gastric, 9 duodenal, and 13 of small intestinal origin. The remaining cases were categorized by location as peripancreatic (n=25), pelvic (n=11), mesenteric (n=4), and of unspecified/miscellaneous sites (n=35). The tumors varied in size 3 to 35 cm (median, 15 cm) and by mitotic rate per 5 mm, 0 to >100 (median, 10). Histologically the tumors apparently arising outside the GI tract had features of intestinal (n=41) and gastric GISTs (n=25); 9 cases had indeterminate histology. The histologic variants included spindled, epithelioid, vacuolated, nested, and myxoid potentially simulating other tumors such as liposarcoma and solitary fibrous tumor. Most GISTs were KIT-positive (106/112 cases), and the remaining 6 tumors were DOG1/Ano1-positive. Five cases showed focal nuclear positivity for MDM2. KIT mutations were detected in 42/59 cases, and PDGFRA mutations in 4/16 KIT wild-type and 3/5 of the KIT-negative tumors analyzed. One pelvic retroperitoneal GIST was succinate dehydrogenase deficient. All 79 patients were dead at last follow-up with a median survival of 14 months, with few survivals >5 years. Only operable versus inoperable tumor was a statistically favorable factor in univariate analysis (P<0.01). In multivariate analysis, mitotic rate >50/5 mm was significant for a shorter survival (hazard ratio, 5.25; 95% confidence interval, 1.65-16.8; P<0.01). Histologic and clinicopathologic similarity of extragastrointestinal retroperitoneal GISTs with GISTs of GI tract suggests their GI tract origin. Potentially overlapping features between GIST and other retroperitoneal tumors necessitate use of multiple diagnostic markers and molecular genetic studies.

Indexed as

DNA Mutational AnalysisImmunohistochemistryMolecular Diagnostic TechniquesAdultAgedAged, 80 and overAnoctamin-1Biomarkers, TumorBiopsyChloride ChannelsFemaleGastrointestinal Stromal TumorsGenetic Predisposition to DiseaseHumansKaplan-Meier EstimateMaleANO1 protein, humanAnoctamin-1Biomarkers, TumorChloride ChannelsNeoplasm ProteinsProto-Oncogene Proteins c-kitReceptor, Platelet-Derived Growth Factor alphaSuccinate Dehydrogenase

Identifiers

PMID28288036
PMCPMC5391299
OpenAlexW2594190043

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.